#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D. — The Peter Attia Drive

✨ AI Summary

Clinical trials of rapamycin in humans underway; dosing strategies, timing, and exercise coordination influence outcomes; two aging models explained—linear decline versus exponential mortality risk
Traditional aging biomarkers lack clinical utility; team developing actionable biological clock to better track meaningful aging processes and intervention responses
Compounds like alpha-ketoglutarate, urolithin A, and NAD boosters show promise; lifestyle interventions including VO2 max training and other approaches demonstrated effective